Mufemilast Phase 2 Data May Partially De-Risk Palisade Bio's PALI-2108

Disclosure: The author holds a beneficial long position in Palisade Bio, Inc. (NASDAQ: PALI) and holds no position in Tianjin Hemay Pharmaceutical. This article is provided for informational and educational purposes only and is not financial advice. Although the author is a Medical Doctor, this content represents a personal analytical perspective on the science and does not constitute medical advice, a diagnosis, or a treatment recommendation. The author receives no compensation for this article and has no business relationship with any of the companies mentioned. Please see the full "Legal Information and Disclosures" section below.

In two prior articles I built a reaction-diffusion model to explore whether PALI-2108's active metabolite can penetrate a fibrotic bowel wall in fibrostenotic Crohn's disease (FSCD), then revisited that model after the Phase 1b FSCD readout. Following a promising Phase 1b readout in ulcerative colitis (UC), Palisade Bio plans a Phase 2 IND submission in the first half of 2026. UC is mucosal rather than transmural, so penetration matters less. After bacterial beta-glucuronidase activates the prodrug in the colon, the active metabolite PALI-0008, a PDE4B/D inhibitor, is released directly onto the inflamed mucosa.

What matters in UC is whether oral PDE4 inhibition can drive clinically meaningful remission at all. PALI-2108's Phase 1b UC cohort (n=5, open-label, 7 days) produced an encouraging signal but cannot settle the question. Earlier systemic agents in the class produced only modest or inconsistent results, and the class has never delivered a clean Phase 2 win in UC. Tianjin Hemay’s Phase 2 mufemilast trial, with double-blind 12-week induction data presented at UEG Week 2025 and 24-week open-label extension data to be presented at DDW 2026, is the strongest signal the class has yet produced.

The induction trial randomized 92 patients with moderate-to-severe UC in China, all having failed at least one prior conventional or advanced therapy, to placebo (n=31), mufemilast 45 mg twice daily (n=31), or 60 mg twice daily (n=30). At Week 12, clinical remission rates were 9.7%, 35.5%, and 43.3% (p=0.031 and p=0.004 versus placebo), with response and mucosal healing showing comparable separation. All participants then received 60 mg twice daily through the open-label extension, and Week 24 remission rates were broadly comparable across original arms. Tolerability was acceptable across 24 weeks, with one possibly drug-related serious adverse event and two discontinuations for adverse events.

For comparison, apremilast has the most UC data in the class. Its 2020 Phase 2 trial (n=170, 61 sites in 14 countries) enrolled biologic-naive patients who had failed, could not tolerate, or had contraindications to conventional therapy. The 30 mg twice daily arm produced a nominally significant remission signal versus placebo (31.6% versus 12.1%, p=0.01), but the higher-dose 40 mg twice daily arm missed (21.8% versus 12.1%, p=0.27), and the program was never advanced into Phase 3 for UC.

Mufemilast shares apremilast's chiral center, 3-ethoxy-4-methoxyphenyl group, methylsulfonyl arm, and acetamido group. PALI-0008's exact structure is not publicly disclosed, but Palisade Bio licensed the Giiant Pharma prodrug platform and benchmarks its preclinical work exclusively against apremilast. PALI-0008 shows roughly 20-fold higher potency than apremilast on whole-blood TNF-α suppression. All three compounds inhibit PDE4 and share downstream cAMP and TNF-α pharmacology, making apremilast the most directly relevant historical baseline within this structural class. The dose-response inversion in apremilast's Phase 2, with the 40 mg arm performing worse than the 30 mg arm, suggests apremilast was tolerability-limited rather than scaffold-limited.

The question for PALI-2108 is whether local activation can deliver enough PDE4 inhibition at the inflamed mucosa without paying the systemic tolerability cost that limited apremilast. In healthy volunteers, the active metabolite reached high colon tissue concentrations while staying low in the bloodstream, consistent with local activation in the gut. Canonical PDE4 side effects trace to systemic PDE4D engagement, which has historically set the dose ceiling for the class.

PALI-2108 has remained clean through Phase 1. The Phase 1a program in 84 healthy volunteers tested single doses up to 450 mg and multiple ascending doses up to 50 mg twice daily, with one moderate-event withdrawal at 50 mg twice daily and no SAEs. The Phase 1b UC cohort on titrated 30 mg twice daily for 7 days produced TEAEs that were predominantly mild and transient (headache, nausea), with no SAEs or discontinuations. The Phase 1b FSCD cohort on once-daily 14-day dosing reported no PDE4 class-related events. Cross-program comparisons have limits given differences in duration, populations, and development stage. Still, mufemilast's two adverse-event discontinuations both occurred in the 60 mg twice daily arm. PALI-2108 produced no discontinuations and no class signal in the FSCD cohort despite reaching plasma IC90 with biopsy-confirmed local target engagement.

The case for PALI-2108 in UC rested on two conditional claims: that oral PDE4 inhibition could produce clinically meaningful remission, and that prodrug architecture could deliver more of it locally without paying the class's tolerability cost. Mufemilast's Phase 2 makes the first more plausible than at any prior point in the class: a 33-percentage-point delta over placebo in a population that includes biologic failures, in a 92-patient single-country trial that still has to read across to global Phase 3. The second claim is harder to evaluate from Phase 1 alone. cAMP rose in the gut wall in both cohorts and the usual PDE4 side effects did not appear, but n=5 over 7 and 14 days does not establish maintained tolerability at therapeutic exposure. PALI-2108's planned Phase 2 in UC is what actually tests whether the local-activation strategy converts these signals into the kind of remission mufemilast has now made plausible for the class.

Follow me on X for frequent updates (@chaotropy).

Legal Information and Disclosures

General Disclaimer & No Financial Advice: The content of this article is for informational and educational purposes only. It represents the personal opinions of the author as of the date of publication and may change without notice. The author is not a registered investment advisor or financial analyst. This content is not intended to be, and shall not be construed as, financial, legal, tax, or investment advice. It does not constitute a personal recommendation or an assessment of suitability for any specific investor. This article does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security. Readers should conduct their own independent due diligence and consult with a certified financial professional before making any investment decisions. This article is not a securities research report and has not been prepared in accordance with legal requirements designed to promote the independence of investment research.

Medical Disclaimer: Although the author possesses a medical background, the information presented here regarding medical technologies, clinical trials, or pharmaceutical mechanisms is strictly for the purpose of educational discussion and general commentary regarding the underlying science. It does not constitute medical advice, a diagnosis, or a treatment recommendation, nor does it establish a physician-patient relationship. Readers should never disregard professional medical advice or delay in seeking it because of something read on this website. Always consult a qualified healthcare provider regarding any medical condition.

Accuracy and Third-Party Data: Clinical trial data, press releases, regulatory filings, and published literature referenced in this article are sourced from ClinicalTrials.gov, company press releases, peer-reviewed journals, and conference abstracts. While the author believes these sources to be reliable, the completeness, timeliness, or correctness of this data cannot be guaranteed. The author assumes no liability for errors, omissions, or the results obtained from the use of this information.

Disclosure of Interest: The author holds a beneficial long position in Palisade Bio, Inc. (NASDAQ: PALI) and holds no position in Tianjin Hemay Pharmaceutical. The author reserves the right to buy or sell these securities at any time without further notice. The author receives no direct compensation for the production of this content and maintains no business relationship with any of the companies mentioned. The author has no access to non-public trial data, unblinded interim results, or internal company information from any of the companies mentioned. Readers should be aware that the author's financial interest in Palisade Bio creates a potential for confirmation bias in the interpretation of publicly available data, despite efforts to mitigate this through citation of primary sources and explicit acknowledgment of competing readings of the evidence.

Forward-Looking Statements & Risk: This article contains forward-looking statements regarding regulatory outcomes (such as FDA decisions), clinical results, and market potential. These statements are predictions based on current expectations and are subject to significant risks and uncertainties. Actual results may differ materially. Investing in biotechnology and pharmaceutical securities involves a high degree of risk, including the potential for total loss of principal. Past performance is not indicative of future results. No reader should rely on this article as a basis for any investment decision. The author has no obligation to update this article if new information becomes available or if the author’s position changes. This content is not directed at or intended for distribution to any person or entity in any jurisdiction where such distribution would be contrary to law or regulation.

Copyright: All original content, including text and images, is the property of the author and may not be copied, reproduced, or published, in whole or in part, without the author's prior written consent, except as permitted by applicable law or the terms of the platform on which it is published. Use of this content for training machine learning or AI models is not permitted without explicit authorization. Third-party or public domain images remain subject to their respective rights and are not claimed as the author's property.